REG - Life Science REIT - Publication of Circular & Notice of GM

Life Science ReitAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251104:nRSD9807Fa&default-theme=true

RNS Number : 9807F  Life Science REIT PLC  04 November 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

4 November 2025

 

Life Science REIT plc

(the "Company" or "LABS")

Publication of Circular and Notice of General Meeting

Further to the announcement on 19 September 2025, the Board of LABS announces
that a circular (the "Circular") has today been published in relation to the
recommended proposal for the Managed Wind-Down of the Company and the
associated adoption of the New Investment Objective and Investment Policy (the
"Proposal"). The Proposal is subject to Shareholder approval and, accordingly,
the Circular contains a notice convening a general meeting of the Company to
be held at the offices of Gowling WLG (UK) LLP, 4 More London Riverside,
London, SE1 2AU (the "General Meeting").

The Board intends that under the proposed Managed Wind-Down process, the
Company will be managed with the intention of realising all the assets in its
portfolio in an orderly manner, with a view to initially repaying borrowings,
followed by making timely returns of capital to Shareholders, whilst aiming to
obtain the best achievable value for the Company's assets at the time of their
realisations. Realisations may take the form of disposals of single assets,
groups of assets or the portfolio as a whole. It is anticipated that the
realisation of the portfolio will be concluded over a 12-18 month period,
depending on, amongst other things, the prevailing market environment.

The adoption of the New Investment Objective and Investment Policy is
conditional on the approval of the Company's Shareholders and is required in
order to implement the Managed Wind-Down. To approve the adoption of the New
Investment Objective and Investment Policy, Shareholders who together
represent a simple majority of the Ordinary Shares voted at the General
Meeting (whether in person or by proxy) must vote to approve the resolution
put to the General Meeting. Shareholders should read the whole of the
Circular, in particular, the letter from the Chair, which contains the
unanimous recommendation of the Board that shareholders vote in favour of the
of the adoption of the New Investment Objective and Investment Policy.

The Board will seek to achieve the most tax-efficient treatment for the
Company's UK Shareholders as a whole at the time of making each return of sale
proceeds, taking into account the composition of the Company's shareholder
register, but as Shareholders' circumstances will vary, it is important that
Shareholders seek their own independent tax and financial advice at all times.

Following realisation of all of the Company's property assets and the return
of proceeds to Shareholders, the Company will seek Shareholders' approval to
cancel: (i) the Company's admission of the Ordinary Shares to the closed-ended
investment funds listing category of the Official List; and (ii) the trading
of the Ordinary Shares on the Main Market of the London Stock Exchange and to
appoint a liquidator to wind up the Company.

General Meeting

The General Meeting has been convened for 2:00 p.m. on 24 November 2025 to be
held at the offices of Gowling LWG (UK) LLP, 4 More London Riverside, London,
SE1 2AU.

 

 

 

Expected timetable of principal events

 Publication of this circular                                                 Tuesday, 4 November 2025
 Latest time and date for receipt of proxy appointments and instructions for  2:00 p.m. on Thursday, 20 November 2025
 the General Meeting
 General Meeting                                                              2:00 p.m. on Monday, 24 November 2025

 

A copy of the Circular will be made available on the Company's website at
https://disclaimer.lifesicencereit.co.uk/investors/
(https://disclaimer.lifesciencereit.co.uk/strategic-review/) and also be
submitted to the National Storage Mechanism, where it will shortly be
available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

Unless otherwise defined, all capitalised terms used in this announcement have
the meanings given to them in the Circular.

The Company's LEI is 213800RG7JNX7K8F7525.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 Life Science REIT plc

 Claire Boyle, Chair                                                            via Panmure Liberum

 MUFG Corporate Governance Limited - Company Secretary

 labs_cosec@cm.mpms.mufg.com

 Panmure Liberum - Financial Adviser & Corporate Broker                         +44 20 7886 2500

 Tom Scrivens / Chris Clarke / Alex Collins / Tim Medak

 G10 Capital Limited - AIFM                                                     +44 20 7397 5450

 Maria Baldwin

 FTI Consulting - PR Adviser

 Dido Laurimore / Richard Gotla / Oliver Parsons                                +44 20 3727 1000

 LifeScienceReit@fticonsulting.com (mailto:LifeScienceReit@fticonsulting.com)

 

 

The person responsible for arranging for the release of this announcement on
behalf of the Company is MUFG Corporate Governance Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGEXLFBEFLEFBF



            Copyright 2019 Regulatory News Service, all rights reserved